Rollins Free cash flow decreased by 30.1% to $111.23M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 20.6%, from $140.11M to $111.23M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 14.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $94.32M | $72.90M | $95.73M | $79.54M | $119.40M | $120.68M | $115.69M | $93.14M | $140.64M | $120.49M | $141.64M | $120.26M | $136.42M | $139.43M | $183.98M | $140.11M | $168.05M | $182.85M | $159.02M | $111.23M |
| QoQ Change | — | -22.7% | +31.3% | -16.9% | +50.1% | +1.1% | -4.1% | -19.5% | +51.0% | -14.3% | +17.6% | -15.1% | +13.4% | +2.2% | +32.0% | -23.8% | +19.9% | +8.8% | -13.0% | -30.1% |
| YoY Change | — | — | — | — | +26.6% | +65.5% | +20.8% | +17.1% | +17.8% | -0.2% | +22.4% | +29.1% | -3.0% | +15.7% | +29.9% | +16.5% | +23.2% | +31.1% | -13.6% | -20.6% |